Dexmedetomidine, Application in Pediatrics: Paper Review

Indian Journal of Pharmaceutical Education and Research

  • María Gabriela Pérez-Guillé1Department Experimental Medicine, Laboratory of Pharmacology, National Institute of Pediatrics, PZ 04530, Mexico City, MEXICO.
  • Chiharu Murata2Department Experimental Medicine, Investigation Methodology, National Institute of Pediatrics, PZ 04530, Mexico City, MEXICO.
  • Rosa Eugenia Reyes-Reyes3Department Experimental Medicine, Cytogenetics Laboratory, National Institute of Pediatrics, PZ 04530, Mexico City, Mexico.
  • Beatríz Pérez-Guillé4Department Experimental Medicine, Laboratory of Experimental Surgery, National Institute of Pediatrics, PZ 04530, Mexico City, MEXICO.
  • José Bobadilla-Chavez5Department Experimental Medicine, Hospital Pharmacy, National Institute of Pediatrics, PZ 04530, Mexico City, Mexico.
  • Radames Alemon-Medina1Department Experimental Medicine, Laboratory of Pharmacology, National Institute of Pediatrics, PZ 04530, Mexico City, MEXICO.
  • Ismene Corral-G6Department Experimental Medicine, Laboratory of Neuro development, National Institute of Pediatrics, PZ 04530, Mexico City, MEXICO.
  • Neydi Osnaya-Romero7Department Experimental Medicine, Unit of support to Clinical Investigation, National Institute of Pediatrics, PZ 04530, Mexico City, MEXICO.

Volume 50 Issue 2s Pages s153-s158

DOI: 10.5530/ijper.50.2.31

Abstract

Introduction: Dexmedetomidine is a drug with sedative, hypnotic, and analgesic properties. Its use in adult sedation was approved in 1999. In children, although the use has not been approved, its application by paediatricians is common. The drug offers many advantages in sedative procedures of paediatric patients. First, the half-life is relatively short. Second, it has little or no effect on respiratory management, and lastly, it is well tolerated by intensive care unit patients found with mechanical ventilation. Pharmacokinetics: 93% of the drug bonds with plasma proteins on absorption. Then, it undergoes a rapid phase of distribution with a half-life of 7 min. It has a depuration rate of 15 ml/kg/min, and half-life elimination rate of 2 h. Pharmacodynamics: The drug has antinociceptive action on α-2A adrenergic receptor of the spinal cord. It has hypnotic-sedative action, and inhibitory effect on central noradrenergic transmission. Applications: It is used as a premedication agent with the objective of getting better cooperation of the patient on starting anaesthetic procedures. Adverse reactions: Bradycardia and hypotension. Conclusion: Its use appears to have a promising future in paediatric population; however, it is pertinent that more controlled clinical studies be carried out in order to demonstrate its safety and efficacy.

Keywords

  • Dexmedetomidine
  • Pharmacokinetic/pharmacodynamic
  • Paediatric patients
  • Adverse reaction
  • Applications
IJOPP

Loading…